Log in

NASDAQ:ALIMAlimera Sciences Stock Price, Forecast & News

$6.07
-0.35 (-5.45 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.03
Now: $6.07
$6.11
50-Day Range
$5.43
MA: $6.01
$6.98
52-Week Range
$2.86
Now: $6.07
$10.35
Volume786 shs
Average Volume41,913 shs
Market Capitalization$30.54 million
P/E RatioN/A
Dividend YieldN/A
Beta2.2
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Read More
Alimera Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALIM
CUSIPN/A
Phone678-990-5740

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.94 million
Book Value($7.53) per share

Profitability

Net Income$-10,440,000.00

Miscellaneous

Employees124
Market Cap$30.54 million
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$6.07
-0.35 (-5.45 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALIM News and Ratings via Email

Sign-up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions

How has Alimera Sciences' stock been impacted by Coronavirus?

Alimera Sciences' stock was trading at $5.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALIM stock has increased by 15.8% and is now trading at $6.07.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Alimera Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Alimera Sciences
.

When is Alimera Sciences' next earnings date?

Alimera Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Alimera Sciences
.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences Inc (NASDAQ:ALIM) issued its earnings results on Wednesday, July, 29th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.14) by $1.63. The biopharmaceutical company earned $10.04 million during the quarter, compared to analyst estimates of $2.30 million.
View Alimera Sciences' earnings history
.

When did Alimera Sciences' stock split? How did Alimera Sciences' stock split work?

Shares of Alimera Sciences reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for ALIM?

2 Wall Street analysts have issued 12-month target prices for Alimera Sciences' stock. Their forecasts range from $14.00 to $15.00. On average, they anticipate Alimera Sciences' stock price to reach $14.50 in the next twelve months. This suggests a possible upside of 138.9% from the stock's current price.
View analysts' price targets for Alimera Sciences
.

Has Alimera Sciences been receiving favorable news coverage?

Media headlines about ALIM stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Alimera Sciences earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the company's share price in the near term.
View the latest news about Alimera Sciences
.

Are investors shorting Alimera Sciences?

Alimera Sciences saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 3,300 shares, an increase of 37.5% from the May 31st total of 2,400 shares. Based on an average daily volume of 22,900 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the shares of the company are sold short.
View Alimera Sciences' Short Interest
.

Who are some of Alimera Sciences' key competitors?

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include Eyepoint Pharmaceuticals (EYPT), Gold Standard Ventures (GSV), Gold Standard Ventures (GSV), VBI Vaccines (VBIV), Opko Health (OPK), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Acasti Pharma (ACST), ADMA Biologics (ADMA) and AngloGold Ashanti (AU).

Who are Alimera Sciences' key executives?

Alimera Sciences' management team includes the following people:
  • Mr. Charles Daniel Myers, Non-Exec. Chairman & Consultant (Age 65)
  • Mr. Richard S. Eiswirth Jr., Pres, CEO & Director (Age 51)
  • Dr. Kenneth Green, Consultant (Age 61)
  • Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets (Age 55)
  • Mr. J. Philip Jones, Chief Financial Officer (Age 55)

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

How do I buy shares of Alimera Sciences?

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $6.07.

How big of a company is Alimera Sciences?

Alimera Sciences has a market capitalization of $30.54 million and generates $53.94 million in revenue each year. The biopharmaceutical company earns $-10,440,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Alimera Sciences employs 124 workers across the globe.

What is Alimera Sciences' official website?

The official website for Alimera Sciences is www.alimerasciences.com.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.